Eric Van Cutsem, MD, PhD

ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC)

Introduction BRAF mutations are found in up to 15% of mCRC, about 90% being V600E, and are associated with poor prognosis. There are no specific therapies approved for BRAFV600...

Eric Van Cutsem , MD, PhD;

07/01/2019

Adjuvant nivolumab vs placebo in resected esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: First report of comprehensive biomarker analyses from CheckMate 577

Adjuvant nivolumab demonstrated statistically significant and clinically meaningful improvement in disease-free survival (DFS) vs placebo and an acceptable safety profile in patients with...

Eric Van Cutsem , MD, PhD;

06/25/2023

A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

Background Combination chemotherapy with fluoropyrimidine and platinum is recommended by the National Comprehensive Cancer Network as a first-line treatment option for p...

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

06/28/2021

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Background In the phase 2 multicohort CheckMate 142 study (NCT02060188), nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety...

S. Abdullaev ;

A. Memaj ;

M. Lei ;

Scott Kopetz , MD, PhD;

M. Overman ;

A. Hill ;

K. Wong ;

T. Andre ;

Eric Van Cutsem , MD, PhD;

Sara Lonardi ;

H. Lenz ;

F. Gelsomino ;

M. Aglietta ;

M. Morse ;

Ryan M. McDermott ;

M. Sawyer ;

A. Hendlisz ;

B. Neyns ;

07/02/2021

TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441)

Introduction Second-line treatment options for advanced pancreatic adenocarcinoma are currently limited. Eryaspase, asparaginase (ASNase) encapsulated in red blood cells (RBCs), is an in...

Eric Van Cutsem , MD, PhD;

07/01/2019

Clinical characteristics, efficacy, and safety in patients receiving second- or third-line encorafenib plus cetuximab (E+C) vs control for metastatic colorectal cancer (mCRC): BEACON CRC post hoc analysis

BRAF mutations occur in 8% to 12% of patients with mCRC and are associated with clinically poor prognosis. E+C was approved by the FDA and EMA for patients with BRAF V600E-mutant mCRC who...

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

06/25/2023

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Background Tucatinib (TUC), a highly selective HER2-directed tyrosine kinase inhibitor (TKI) approved in multiple regions for HER2+ metastatic breast cancer, is being de...

Eric Van Cutsem , MD, PhD;

06/28/2021

Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib + cetuximab +/- binimetinib in BEACON CRC

Background Approximately 10% of patients with metastatic colorectal cancer (mCRC) have BRAF mutations, predominantly V600E. Encorafenib has been approved in combination with cetuximab in ...

Eric Van Cutsem , MD, PhD;

07/02/2021

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study

Introduction Combination therapy with the anti-HER2 antibody trastuzumab with fluoropyrimidine and platinum is the current standard for patients with HER2+ metastatic gastric or gas...

Eric Van Cutsem , MD, PhD;

07/01/2019

The SUNLIGHT trial, an international, open-label, randomised, phase 3 study comparing trifluridine/tipiracil (FTD/TPI) plus bevacizumab (bev) to FTD/TPI monotherapy in patients with refra...

Eric Van Cutsem , MD, PhD;

06/25/2023